RSR-13, an allosteric hemoglobin modifier, evaluated in GBM in combination with cranial radiotherapy May 19, 1999
Potent, water-soluble paclitaxel analogue in early clinical trials presented by BMS at ASCO meeting May 19, 1999
Phase I results for endothelin antagonist discussed at ASCO meeting; phase II trials under way May 19, 1999
BASF patents new tyrosine kinase inhibitors for hyperproliferative and angiogenic disorders May 19, 1999
Orally active antimetabolite CS-682 well tolerated in patients with refractory solid tumors May 18, 1999
RSS